Iambic Therapeutics (NASDAQ:IAM) Director Purchases 718,750 Shares of Stock

Iambic Therapeutics, Inc. (NASDAQ:IAM) Director Evan Lockwood Rachlin acquired 718,750 shares of the business’s stock in a transaction on Friday, October 16th. The shares were bought at an average cost of $16.00 per share, with a total value of $11,500,000.00. Following the completion of the acquisition, the director owned 2,588,248 shares in the company, valued at approximately $41,411,968. This represents a 38.45% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Iambic Therapeutics Trading Down 31.4%

Shares of Iambic Therapeutics stock traded down $7.47 on Monday, hitting $16.34. 2,381,958 shares of the company traded hands, compared to its average volume of 2,673,314. Iambic Therapeutics, Inc. has a 52 week low of $14.10 and a 52 week high of $25.00.

Iambic Therapeutics Company Profile

Iambic Therapeutics, Inc (NASDAQ: IAM) is a clinical-stage biotechnology company focused on discovering and developing novel medicines, with an emphasis on small-molecule therapies. The company combines artificial intelligence, computational modeling and experimental drug discovery methods to identify potential drug candidates and accelerate the development process.

Iambic’s technology platform is designed to support multiple stages of pharmaceutical research, including target evaluation, molecule design, compound testing and optimization.